In this context, ADRA2C, which is upregulated in AML with t(8;21), could be an interesting target to explore, because many agonists and antagonists of this receptor are available, including several FDA-approved drugs such as the antihypertensive drug clonidine and the antidepressant Mirtazapine. This evidence concerns the gene ADRA2C and acute myeloid leukemia.